TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

ERYTHRA-DERM

ERYTHROMYCIN
Dermatology Approved 1988-02-05
Jump to: Indications Approvals Trials Competitors Similar Safety Patents
1
Indication
--
Phase 3 Trials
38
Years on Market

Details

Status
Prescription
First Approved
1988-02-05
Routes
TOPICAL
Dosage Forms
SOLUTION

Companies

MICRO LABS
Active Ingredient: ERYTHROMYCIN

ERYTHRA-DERM Approval History

Loading approval history...

What ERYTHRA-DERM Treats

1 indications

ERYTHRA-DERM is approved for 1 conditions since its original approval in 1988. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Acne Vulgaris
Source: FDA Label

Drugs Similar to ERYTHRA-DERM

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

ACANYA
BENZOYL PEROXIDE
1 shared
BAUSCH
Shared indications:
Acne Vulgaris
ACZONE
DAPSONE
1 shared
ALMIRALL
Shared indications:
Acne Vulgaris
ADAPALENE AND BENZOYL PEROXIDE
ADAPALENE
1 shared
PADAGIS ISRAEL
Shared indications:
Acne Vulgaris
AKLIEF
TRIFAROTENE
1 shared
GALDERMA LABS LP
Shared indications:
Acne Vulgaris
ALTRENO
TRETINOIN
1 shared
DOW PHARM
Shared indications:
Acne Vulgaris
AMZEEQ
MINOCYCLINE HYDROCHLORIDE
1 shared
JOURNEY
Shared indications:
Acne Vulgaris
ARAZLO
TAZAROTENE
1 shared
BAUSCH
Shared indications:
Acne Vulgaris
ATRALIN
TRETINOIN
1 shared
DOW PHARM
Shared indications:
Acne Vulgaris
AVAGE
TAZAROTENE
1 shared
ALMIRALL
Shared indications:
Acne Vulgaris
AZELEX
AZELAIC ACID
1 shared
ALMIRALL
Shared indications:
Acne Vulgaris
BENZAMYCIN
BENZOYL PEROXIDE
1 shared
VALEANT INTL
Shared indications:
Acne Vulgaris
CABTREO
ADAPALENE
1 shared
BAUSCH
Shared indications:
Acne Vulgaris
CLEOCIN T
CLINDAMYCIN PHOSPHATE
1 shared
Pfizer
Shared indications:
Acne Vulgaris
CLINDA-DERM
CLINDAMYCIN PHOSPHATE
1 shared
PADAGIS US
Shared indications:
Acne Vulgaris
CLINDAGEL
CLINDAMYCIN PHOSPHATE
1 shared
BAUSCH
Shared indications:
Acne Vulgaris
CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE
1 shared
TARO
Shared indications:
Acne Vulgaris
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE
BENZOYL PEROXIDE
1 shared
Teva
Shared indications:
Acne Vulgaris
CLINDAMYCIN PHOSPHATE AND TRETINOIN
CLINDAMYCIN PHOSPHATE
1 shared
SOLARIS PHARMA CORP
Shared indications:
Acne Vulgaris
CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE
CLINDAMYCIN PHOSPHATE
1 shared
Baxter
Shared indications:
Acne Vulgaris
CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER
CLINDAMYCIN PHOSPHATE
1 shared
RISING
Shared indications:
Acne Vulgaris
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

ERYTHRA-DERM FDA Label Details

Pro

Indications & Usage

Erythromycin Topical Solution USP, 2% is indicated for the topical treatment of acne vulgaris.

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

FDA Approval: ANDA062687 → Label: DailyMed → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.